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        A major challenge to tumor immunology is to 
identify and elicit protective mechanisms that 
parallel the more powerful immune responses 
that are seen in other settings, such as resistance 
to infection and rejection of transplants (  1  ). 
However, it has been diffi   cult to induce strong 
immunity to tumors, particularly T cells that 
recognize multiple antigens in tumor cells and 
diff  erentiate to express helper and killer func-
tions, as well as memory. 
  One way to improve T cell –  based resistance 
to tumors is to expand tumor-reactive lympho-
cytes to large numbers ex vivo and then reinfuse 
them back into patients. Measurable resistance 
develops after such passive immunotherapy 
with CD8     T cells in humans (  2  –  4  ). Another 
approach is the active induction of resistance 
to tumors in vivo. Certain chemotherapies can 
elicit some immunity to tumors, because the 
dying tumor cell is both recognized by DCs and 
matures the DCs to induce immunity, although 
the tumor resistance is partial (  5, 6  ). Stronger 
resistance can be induced when DCs take up 
irradiated tumor cells injected i.v.; then, the 
DCs are matured through activated NKT lym-
phocytes or by a combination of an agonistic 
anti-CD40 antibody and a ligand for Toll-like 
receptors (  7  ). However, this pathway requires 
large numbers of tumor cells, which for some 
tumors like the B16 melanoma, is toxic. It is 
important to identify pathways that allow tumor 
cells to more effi   ciently induce long-lived, spe-
cifi  c, T cell  –  mediated immunity. 
  In this paper, we report a mechanism that 
induces potent T cell immunity to several poorly 
immunogenic, transplantable mouse tumors, 
including the B16 melanoma. The mechanism 
depends on the capacity of DCs in the spleen 
to take up and cross-present dying cells (  8  ). 
Previous research has emphasized the cross-
presentation of protein antigens onto MHC class I 
products permitting the generation of CD8     
killer T cells (  7, 9  ). We now describe the cross-
presentation of glycolipids on CD1d molecules 
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  We report a mechanism to induce combined and long-lived CD4     and CD8     T cell immunity 
to several mouse tumors. Surprisingly, the initial source of antigen is a single low dose of 
tumor cells loaded with     -galactosylceramide (    -GalCer) glycolipid (tumor/Gal) but lacking 
co-stimulatory molecules. After tumor/Gal injection intravenously (i.v.), innate NKT and NK 
cells reject the tumor cells, some of which are taken up by dendritic cells (DCs). The DCs in 
turn cross-present glycolipid on CD1d molecules to NKT cells and undergo maturation. For 
B16 melanoma cells loaded with     -GalCer (B16/Gal), interferon       –  producing CD8     T cells 
develop toward several melanoma peptides, again after a single low i.v. dose of B16/Gal. In 
all four poorly immunogenic tumors tested, a single dose of tumor/Gal i.v. allows mice to 
become resistant to tumors given subcutaneously. Resistance requires CD4     and CD8     cells, 
as well as DCs, and persists for 6  –  12 mo. Therefore, several immunogenic features of DCs 
are engaged by the CD1d-mediated cross-presentation of glycolipid-loaded tumor cells, 
leading to particularly strong and long-lived adaptive immunity. 2642 ADAPTIVE TUMOR IMMUNITY INDUCED BY GLYCOLIPID-LOADED TUMOR CELLS | Shimizu et al.
be induced by an injection of DCs loaded with     -GalCer 
(DC/Gal), because we had reported that DC/Gal can acti-
vate NK and NKT cells and protect against metastasis of 
i.v.-injected B16 to the lung (  12, 13  ). However, mice given 
DC/Gal did not protect against B16 challenge s.c. (  Fig. 1 A  ) 
or challenge with EL4 thymoma s.c. (not depicted). This was 
also the case for s.c.-injected B16/Gal and with tumor cells 
that had been transfected to express high levels of CD1d and 
loaded with     -GalCer (CD1d  hi  -B16/Gal;   Fig. 1 B  ). 
  Unexpectedly, if we fi  rst injected mice with live B16/Gal 
i.v. and then challenged the mice with B16 tumor cells 
s.c. 2 wk later, 6 out of 10 animals now showed resistance 
(  Fig. 1 C  ). If we injected transfected CD1d  hi  -B16/Gal i.v., all 
the mice became resistant to a challenge with B16 tumor s.c 
(  Fig. 1 D , left). This resistance proved to be T cell mediated. 
Thus, CD4      /      and CD8      /      mice did not develop resistance 
to a subsequent s.c. challenge with B16 tumor cells (  Fig. 1 D  , 
right), although the knockout mice eff  ectively resisted the 
growth of the initial inoculum of living CD1d  hi  -B16/Gal 
tumor cells given i.v. by innate mechanisms, as shown previ-
ously (  11  ). The fi  nding that lung metastases were still inhib-
ited when B16/Gal or CD1d  hi  -B16/Gal were administered 
in vivo. Cross-presentation of glycolipids has been noted in 
one previous study in tissue culture (  10  ), but in vivo con-
sequences could not be assessed. We fi  nd that the i.v. adminis-
tration of either live or irradiated tumor cells, which have 
been loaded with the agonistic glycolipid     -galactosylce-
ramide (    -GalCer), fi  rst elicits an innate NKT and NK cell 
response that rejects the tumor, including cells that have been 
administered 3 d previously (  11  ). This approach, even though 
it involves a single low dose of tumor cells lacking in co-
stimulatory molecules, leads to a second NKT cell response 
to glycolipid cross-presented by DCs. The DCs then mature 
and induce combined CD4     and CD8     protective T cell im-
munity to the captured tumor cells. 
    RESULTS   
  Vaccination with B16 melanoma cells loaded with     -GalCer 
(B16/Gal) induces T cell  –  dependent antitumor resistance 
  The mouse B16 melanoma expresses little or no MHC pro-
ducts or co-stimulatory molecules (e.g., CD40 and CD86) 
and is poorly immunogenic. When injected s.c. into syngeneic 
C57BL/6 mice, it grows rapidly and overcomes all animals 
(  Fig. 1 A  ).   We evaluated whether protection against B16 could 
  Figure 1.     Vaccination with B16/Gal induces T cell  –  dependent antitumor resistance. (A) 10  6      -GalCer  –  loaded DCs per mouse were administered 
to mice. 10  5   B16 melanoma tumor cells were injected s.c. 2 wk later. Measurement of tumor size was done at the indicated time points (  n    5 per group). 
Similar results were obtained in two independent experiments. (B) 10  5   B16/Gal or nonloaded B16 melanoma cells per mouse were administered s.c., and 
tumor size was followed (  n    5 per group). Similar results were obtained in two independent experiments. (C and D, left) 5      10 5     -GalCer – loaded  B16 
or CD1d  hi  -B16 tumor cells per mouse were given i.v., and 2 wk later mice were challenged with 10  5   parental B16 tumors s.c. (  n    10 per group). Similar 
results were obtained in two independent experiments. (D, right) At 2 wk after vaccination of CD4     /   ,  CD8    /    , and MHC II     /     mice with 5      10 5   CD1d hi -
B16/Gal i.v., the mice were challenged s.c. with B16 tumor cells (  n    5 per group). Similar results were obtained in two independent experiments. 
(E) CD19     B cells were isolated with magnetic beads from the spleen, coated with     -GalCer, and injected together with irradiated CD1d  hi  -B16 cells (  n    5 
per group). Data are means      SEM. Similar results were obtained in two independent experiments.     JEM VOL. 204, October 29, 2007 
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  resistance of CD4      /      mice to tumor administered s.c. diff  ers 
from our previous study showing innate resistance to     -GalCer  – 
loaded tumor cells given i.v. (  11  ). With the i.v. route, trans-
plantable tumors, including B16 melanoma, are rejected 
by innate NKT cells (especially CD4        NKT cells) and NK 
cells without the need for adaptive CD4     or CD8     T cell 
immunity (  11  ). Collectively, the results, which show the 
induction of protective T cell immunity to B16 melanoma, 
were surprising because it has been so diffi   cult to raise T cell 
responses to this tumor, especially with a single and low dose 
of tumor cells. 
  Finally, to demonstrate that the     -GalCer needed to be 
loaded on the tumor cells and could not be transferred from 
or induced by     -GalCer on other cells, we injected a mixture 
of     -GalCer  –  loaded, splenic B cells plus irradiated CD1d  hi  -
B16 cells that were not loaded with     -GalCer. Mice given 
irradiated CD1d  hi  -B16 cells alone did not develop resistance, 
and this was also the case when mice were given     -GalCer  –
  loaded B cells plus irradiated CD1d  hi  -B16 cells (  Fig. 1 E  ). 
The latter data indicate that     -GalCer does not elute in suffi   -
cient amounts to coat CD1d  hi  -B16 cells, in contrast to tumor 
to CD4      /      mice was surprising, in that CD4     NKT cells 
seemed dispensable for providing innate immunity. The 
data may be consistent with Crowe et al., who reported 
that CD4        NKT cells showed stronger antitumor immunity 
than CD4     NKT cells (  14  ). However, CD4        NKT cells in 
CD4      /      mice may include cells that are equivalent to CD4     
NKT cells in WT mice. Therefore, we also tested whether 
antitumor eff  ects develop in MHC II      /      mice that would 
not have conventional CD4     T cells. Fig. S1 (available at 
http://www.jem.org/cgi/content/full/jem.20070458/DC1) 
shows that MHC II      /      mice had CD4     CD1d-dimer     NKT 
cells and some CD4     CD1d-dimer        T cells (  15, 16  ). The 
latter may include T cells that are not MHC II restricted, 
as well as some type 2 NKT cells or MR1-restricted cells. 
When we gave tumor cells loaded with     -GalCer (tumor/Gal) 
to MHC II      /      mice, resistance to B16 melanoma did not 
develop (  Fig. 1 D  , right), although the mice showed de-
layed rejection of     1 wk, presumably caused by the residual 
CD4     T cells (Fig. S1). In contrast, as shown in   Fig. 1 D  , 
CD4     T cells were required to induce adaptive antitumor 
immunity to s.c. challenge with tumor. The lack of adaptive 
  Figure 2.     Vaccination with B16-GalCer tumor cells i.v.   leads to T cell immunity to several defi  ned melanoma differentiation antigens.   
(A) Mice were injected i.v. with 5      10 5   B16, B16/Gal, CD1d  hi  -B16, or CD1d  hi  -B16/Gal. To monitor antigen-specifi  c T cell responses 1 and 4 wk later, CD8    
T cells were positively selected from the spleen and were cultured with splenic CD11c     DCs from naive mice for 36 h. The DCs had been cultured for 2 h in 
the presence or absence of 10    M  gp100 25 –  33  ,  Trp2 180 –  188  ,  Tyrp 455 –  463  ,  Tyrp 522 –  529   , or Dct  363 –  371    peptides. T cells responding to the DCs were detected by 
ELISPOT assay for IFN-  	   production. All data are means      SEM obtained from three independent experiments with two mice per group. *, P   
   0.05  for 
B16/G versus CD1d  hi  -B16/G. (B) As in A, but the immune responses were monitored with intracellular cytokine staining. CD8     T cells were magnetically 
isolated from the spleen 7 d after i.v. CD1d  hi  -B16/Gal. The CD8     T cells were co-cultured for 16 h with splenic CD11c     DCs from naive mice in the pres-
ence of brefeldin A, which had been pulsed with 10    M  Trp2 180 –  188    peptide for 2 h, for the last 10 h. Numbers indicate the percentage of total CD8     cells. 
The data are representative of three independent experiments (  n    4 per group). (C) Mice were immunized with 5      10 5   CD1d hi  -B16/Gal and depleted 
NK1.1     cells by injections of 300     g of anti-NK1.1(PK136) antibody per mouse at days   −  1, 3, and 5 (before vaccination), or days 3 and 5 (after vaccination). 
As in A, the TRP2-specifi  c CD8     T cell response was detected by ELISPOT assay for IFN-  	   at day 7. Data are means      SEM obtained from three independent 
experiments (  n    4 per group). **, P   
   0.01.   2644 ADAPTIVE TUMOR IMMUNITY INDUCED BY GLYCOLIPID-LOADED TUMOR CELLS | Shimizu et al.
  Figure 3.     Vaccination with live and irradiated tumor/Gal induces antitumor protection against several mouse tumors. (A, left) Immunization 
experiments were set up as shown; i.e., mice were vaccinated with 5      10 6   of different forms of J558 myeloma cells, challenged at 4 wk with 10  6   live 
J558 s.c., and evaluated for their survival (  n    10 per group). Similar results were obtained in two independent experiments. (B) Mice were injected i.v. 
with 5      10 5   live and irradiated CD1d  hi -B16/Gal  ( n    9 and 6 per group, respectively), 2      10 6   CD1d hi -WEHI-3B/Gal  ( n    5 per group), or 5      10 5  
CD1d  hi -EL4/Gal  ( n    8 and 5 per group, respectively). The mice were challenged s.c. with parental tumor cells (5      10 4   B16, 2      10 5   WEHI-3B, or 2      10 5  
EL4) 4 wk later. Tumor sizes were measured at the indicated time points. Similar results were obtained in two independent experiments. (C) Mice were JEM VOL. 204, October 29, 2007 
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challenged the mice with tumor cells injected s.c. but with-
out any loading with     -GalCer. In each case, the mice were 
resistant to s.c. challenge of the original tumor, which was 
otherwise lethal (  Fig. 3 B  ). We also vaccinated WT, CD4      /     , 
and CD8      /      mice with 5      10  5   CD1d  hi  -EL4/Gal i.v. and 
challenged the mice 2 wk later s.c. with 2      10  5   parental 
EL4 tumor cells; the WT mice were immune, but the T cell  – 
depleted mice were not (Fig. S2, available at http://www
.jem.org/cgi/content/full/jem.20070458/DC1). In the case 
of B16, we rechallenged the mice with B16 or EL4 at 12 mo 
after rejecting tumor. Again, such mice showed the protec-
tion against B16 tumors but not EL4 tumors, indicating the 
establishment of protective long-term memory in a tumor-
specifi  c manner (  Fig. 3 C  ). We likewise observed protection 
for 1 yr when we vaccinated with CD1d  hi  -J558/Gal tumor 
(Fig. S3). Therefore, several tumors can induce resistance 
when exposed to     -GalCer and injected i.v. in relatively low 
doses into mice. 
      -GalCer  –  loaded tumor cells are superior inducers of T cell 
immunity to DCs injected i.v. 
  Because the immune response to a single dose of co-stimulator  – 
poor tumor/Gal was strong relative to the existing literature, 
we further compared tumor/Gal with DC/Gal. OVA was 
used as a surrogate antigen, because this provided a highly 
sensitive readout for CD8     T cell immunity caused by the 
effi   cacy with which the SIINFEKL peptide from OVA is 
presented on H-2K  b   MHC class I molecules. EL4 or CD1d  hi  -
EL4 tumor cells were exposed to an osmotic shock in the 
presence of 10 mg/ml OVA protein (resulting in     100 ng 
OVA protein per 10  6   cells, as measured by ELISA; Morinaga 
Institute of Biological Science, Inc.). To monitor the pro-
cessing and presentation of the tumor cells on MHC class I 
and II, we fi  rst adoptively transferred CFSE-labeled OT-I 
and OT-II OVA-specifi  c TCR transgenic T cells as reporters, 
and then injected 2      10  6       -GalCer  –  loaded EL4(OVA) or 
CD1d  hi  -EL4(OVA) cells (  Fig. 4 A  , top).   The injection of 
tumor cells induced strong proliferation in both CD4     and 
CD8     T cells, and the up-regulation of the CD25 high affi   n-
ity receptor for IL-2 (mean of CD25    -proliferated T cells  
1.65, 22.65, 2.74, and 59.8% in EL4(OVA), EL4(OVA)/Gal, 
CD1d  hi  -EL4(OVA), and CD1d  hi  -EL4(OVA)/Gal, respectively; 
  Fig. 4 A  , top). For CD8     OT-I cells, stimulation of cell divi-
sion was dependent on the presence of transporter associated 
with antigen presentation (TAP) molecules in the recipient mice 
(  Fig. 4 A  , bottom). This indicates that injected EL4(OVA) 
cells were cross-presented by TAP-expressing antigen-pre-
senting cells in the host. To implicate DCs during cross-
presentation, we depleted DCs using a transgenic mouse in 
which the CD11c promoter drives expression of the diph-
theria toxin receptor (DTR); this allows depletion of CD11c-
rich DCs after injection of DT and eliminates cross-presentation 
cells directly loaded with     -GalCer (  Fig. 1 D  ). Collectively, 
the results in   Fig. 1   indicate that     -GalCer  –  loaded tumor 
cells in relatively small numbers are able to induce T cell re-
sistance to an s.c. challenge with B16 melanoma. 
  Vaccination with B16/Gal i.v. induces T cells specifi  c 
for defi  ned melanoma differentiation antigens 
  Another manifestation of the weak immunogenicity of B16 
melanoma is the diffi   culty in detecting responses to defi  ned 
melanoma antigens by ELISPOT and intracellular cytokine 
staining assays. However, when we injected CD1d  hi  -B16/Gal 
tumor cells and looked for CD8     T cells specifi  c for mela-
noma antigens 1 wk later, we could detect IFN-  	    –  producing 
cells responsive to several diff  erent MHC class I  –  binding, 
nonamer peptides; these included peptides from the gp100, 
tryrosinase-related, and dopachrome tautomerase (DCT)/
tyrosinase-related protein 2 (TRP-2) antigens (  Fig. 2 A  , left) 
(  17, 18  ).   Some of these cytokine-producing T cells persisted 
for 4 wk (  Fig. 2 A  , right). After immunization with B16/Gal, 
we also detected IFN- 	    –  producing CD8     cells, but in smaller 
numbers than CD1d  hi  -B16/Gal (  Fig. 2 A  ). We additionally 
documented TRP-2  –  specifi  c, CD8     T cells using an intra-
cellular cytokine staining assay after injection of B16/Gal or 
CD1d  hi  -B16/Gal but not tumor cells lacking     -GalCer (0.16      
0.04, 0.22      0.06, and     0.05 in B16/Gal, CD1d  hi  -B16/Gal, 
and others, respectively;   Fig. 2 B  ). Again, even if we com-
pletely deleted NK1.1     cells by anti-NK1.1 antibody treat-
ment 3 and 5 d after vaccination, T cell immunity developed 
to tumor/Gal; however, if we deleted NK1.1     cells before 
immunization, T cell immunity was almost abolished (  Fig. 2 C  ). 
These results indicate that once T cell immunity was initi-
ated, the mice no longer needed NK1.1     cells. The detection 
of melanoma-specifi  c CD8     T cell responses with a single 
dose of     -GalCer  –  modifi  ed tumor cells was of some interest 
given previous diffi   culties in eliciting immunity to this par-
ticular tumor. 
  Several     -GalCer  –  loaded tumors injected i.v. establish 
resistance to native tumor 
  To extend the analysis to other tumors, we studied the J558 
plasmacytoma. J558 also grew rapidly when injected s.c., and 
the mice did not survive (  Fig. 3 A  , open squares).     However, 
if we fi  rst injected the tumor or its CD1d transfectant i.v. 
(each loaded with     -GalCer), then the animals developed 
resistance to an otherwise lethal s.c. challenge with J558 
(  Fig. 3 A  ). We next compared the B16 melanoma in   Figs. 
1 and 2   with the EL4 thymoma and WEHI-3B acute myelo-
monocytic leukemia, each of which grew aggressively in 
mice after s.c. inoculation (  Fig. 3 B  ). We had previously 
shown that these     -GalCer  –  coated tumors elicited strong NKT 
cell  –  dependent innate resistance (  11  ). 4 wk after injecting 
    -GalCer  –  loaded, live, or irradiated CD1d  hi   tumors i.v., we 
immunized and challenged as indicated in the diagram (  n    5 B16 or EL4;   n    9 tumor/Gal-B16   –  EL4). Data are means      SEM. Similar results were 
obtained in two independent experiments.     
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  Figure 4.     DCs are less effective than tumor/Gal in presenting OVA antigen when injected via the i.v.   route.       (A) Mice were adoptively trans-
ferred with 2      10 6   CFSE-labeled OT-I cells and were immunized the next day with EL4(OVA) or CD1d  hi -EL4(OVA)      Gal. 3 d later, the animals were tested 
for proliferation of transferred OT-I cells as well as CD25 (top). Data are representative of two separate experiments (  n    2 per group). Different strains 
of C57BL/6 mice (bottom) were adoptively transferred with 2      10 6   CFSE-labeled OT-I cells or OT-II T cells and then challenged with 2      10 6   CD1d hi -
EL4(OVA)/Gal cells i.v. 3 d later, cell proliferation was monitored in the spleen by CFSE dilution (bottom). Naive indicates OT-I or OT-II cell-transferred, but 
not immunized, mice. The numbers indicate CD25     (top) or CD25        (bottom) differentiated OT-I cells. Data are representative of three separate experi-
ments (  n    3 per group). (B) As in A, but now the immune response was measured in naive and immunized mice using H-2K  b  /OVA tetramers 7 d later. 
Mice were injected i.v. with 2      10 6   BM-derived DCs that had been pulsed with 1    M  OVA 257 –  264    peptide in the absence or presence of 100 ng/ml
     -GalCer. The expansion of OVA-specifi  c CD8     T cells was compared with different forms of 2      10 6   EL4 tumors that were loaded with OVA (see Materials 
and methods) in the absence or presence of     -GalCer. Data are representative of four separate experiments (  n    4 per group). (C) The expansion of OVA-
specifi  c CD8     T cells was shown. Mice were immunized with 100     g OVA peptide per mouse with or without 1     g of free     -GalCer i.v. per mouse (refer-
ence   20  ). Data are representative of four separate experiments (  n    4 per group). Gated cells in B and C indicate CD8     K b /OVA 257 –  264      double-positive 
cells using K  b /OVA 257 –  264    tetramer  –  PE and CD8-FITC. (D) As in B, but the immune response was measured with an intracellular cytokine staining. 7 d after 
immunization, spleen cells were cultured with or without OVA  257 –  264    peptide to stimulate OVA-specifi  c CD8     T cells for 6 h, and T cell production of IFN-  	   was JEM VOL. 204, October 29, 2007 
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spleen cells injected i.v., because allogeneic cells are killed by 
NK cells (  8  ) (Fig. S5, available at http://www.jem.org/cgi/
content/full/jem.20070458/DC1). Then, to follow uptake 
of the tumor cells, we performed experiments with CFSE-
labeled EL4 tumor rather than B16 at fi  rst, because higher 
doses of tumor cells are needed to detect tumor cell uptake by 
FACS and B16 is toxic when     10  6   cells are given i.v. By fl  ow 
cytometry and confocal microscopy, we observed that CD8         
DCs picked up the injected CFSE-labeled live CD1d  hi  -EL4/
Gal 10 h later (CFSE-positive cells from total CD11c     DCs  
3.38      0.39% and   
  0.01% in CD1d  hi  -EL4/Gal  –  injected 
mice and naive C57BL/6 mice, respectively;   Fig. 5, A  –  C  ).   
When uptake kinetics were followed, the DCs in WT mice 
had CFSE     debris for at least 24 h after tumor/Gal admin-
istration, but not in J    18      /      mice (  Fig. 5, C and D  ). We 
interpret these fi  ndings to indicate that the presentation of 
    -GalCer on tumor cells leads to killing by NKT and/or NK 
cells, followed by uptake by CD8         DCs. 
  DC maturation in response to         -GalCer  –  loaded tumor 
cells i.v. 
  To explain the T cell response to injected tumor/Gal, we rea-
soned that the DCs capturing tumor had to be undergoing 
diff  erentiation or maturation. We initially examined several 
cell-surface molecules after injecting tumor/Gal (  Fig. 6   and 
Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20070458/DC1).   CD86 expression on both CD8         and 
CD8            subsets of DCs began to increase within hours of 
injecting CD1d  hi  -B16/Gal (tumor/Gal;   Fig. 6 A  ). We also ob-
served up-regulation of CD40 and CD80 and down-regulation 
of CD119 (Fig. S6), which are characteristic changes for DCs 
undergoing maturation in vivo (  9  ). To assess DCs in other tis-
sues, we compared spleen with lung and liver, and again there 
was a clear increase in CD86 expression if we injected tumor/
Gal as opposed to native tumor (  Fig. 6 B  , compare fi  lled and 
open tracings). The increase in CD86 expression after the in-
jection of     -GalCer  –  loaded tumor was similar to that seen 
with free     -GalCer (  Fig. 6 B  ), a particularly powerful stimulus 
for DC maturation (  9, 21, 22  ), indicating that tumor/Gal 
were surprisingly able to mimic the agonistic glycolipid itself. 
  Another manifestation of maturation is that DCs start to 
produce protective cytokines like IL-12. In fact, IL-12 was 
induced within 4 h of giving mice B16/Gal or CD1d  hi  -B16/
Gal i.v. but not tumor cells without     -GalCer (  Fig. 6 C  , 
compare left and right panels). To establish the need for NKT 
cells to bring about DC maturation, we assessed cell-surface 
markers and IL-12 production by DCs in J    18      /      mice given 
tumor/Gal. Both signs of maturation were ablated in the ab-
sence of NKT cells (IL-12p40/p70  –  positive CD8     cells from 
of many forms of antigen (  19  ). Treatment with DT totally 
ablated the presentation of OVA from the injected tumor 
cells to OT-I and OT-II transgenic T cells (  Fig. 4 A  ). These re-
sults indicate that DCs cross-present antigens from     -GalCer  – 
loaded EL4 thymoma cells. 
  We next studied the CD8     T cell response in naive mice, 
i.e., in the absence of transferred transgenic T cells. Much 
stronger responses to DCs were noted when we used the more 
standard s.c. route of DC administration (Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20070458/DC1). 
However, DCs coated with peptide with or without     -GalCer 
were poorly immunogenic when given by the i.v. as well 
as the s.c. route (  Fig. 4, B and D  ; and Fig. S4). In contrast, 
EL4(OVA) tumor cells induced stronger immunity if the cells 
were loaded with     -GalCer and injected i.v. (  Fig. 4, B and D  ), 
but not when given s.c. The OVA immune responses could 
be observed by measuring the numbers of OVA-specifi  c 
CD8     T cells with H-2K  b  /OVA tetramers (tetramer-pos-
itive CD8     T cells  0.59      0.16, 0.38      0.21, 0.52      
0.01, 3.03      0.61, 0.44      0.16, 7.71      1.62, and 0.11      
0.06 in DC-pep  –  , DC-pep/G  –  , EL4(OVA)-, EL4(OVA)/
Gal-, CD1d  hi  -EL4(OVA)  –  , and CD1d  hi  -EL4(OVA)/Gal  –
  injected mice and naive C57BL/6 mice, respectively;   Fig. 
4 B  ) or with intracellular cytokine staining for IFN-  	   pro-
duction (  Fig. 4 D  ). The response to tumor/Gal was entirely 
dependent on the presence of V    14     NKT cells, TAP, and 
CD40, as indicated with the appropriate knockout mice (  Fig. 
4 E  ). Silk et al. previously reported on immune responses to 
the combination of peptide and     -GalCer given i.v. (  20  ), 
so we repeated their protocol with 100     g OVA peptide as 
a model antigen plus     -GalCer. We detected just 0.49      
0.19% tetramer-positive CD8     T cells in the spleen, which 
was 20 times smaller than we observed when we injected 
CD1d  hi  -EL4(OVA)/Gal into mice i.v. (tetramer-positive CD8     
T cells  0.03      0.02 and 0.49      0.19 in OVApep- and 
OVApep plus Gal  –  injected mice, respectively;   Fig. 4 C  ). 
These data indicate that tumor/Gal are more immunogenic 
than DCs if the i.v. route of immunization is used, but that 
immunity requires V    14    NKT cells and TAP     DCs in the 
recipient mice. 
  DCs capture tumor cells after i.v. injection of tumor/Gal 
  To begin to understand the immunogenicity of co-  stimulator  –
  poor tumor/Gal, we pursued previous fi  ndings that CD8         
DCs in mouse spleen captured dying cells when the latter 
were administered by the i.v. route (  8  ). We reasoned that 
killing of the injected tumor/Gal tumor by NKT and NK 
cells would provide a source of dying tumor for DCs. We 
fi  rst verifi  ed that CD8         DCs were able to capture allogeneic 
measured by intracellular cytokine staining. Data are means      SEM obtained from fi  ve mice per group in three independent experiments. *, P   
   0.05  for 
EL4(OVA)/G or CD1d  hi  -EL4(OVA)/G versus the other groups and EL4(OVA)/G versus CD1d  hi  -EL4(OVA)/G). (E) J   18    /   ,  CD4    /   ,  TAP    /    , or CD40     /     mice 
were used as recipients for CD1d  hi  -EL4(OVA)/Gal, and the immune responses were tested by intracellular cytokine staining in the absence or presence of 
OVA peptide 1 wk later. Data are means      SEM obtained from fi  ve mice per group in three independent experiments. *, P   
   0.05 for WT versus J   18    /   , 
TAP     /    , or CD40     /    ; P      0.05 for WT versus CD4     /   .   
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CD11c     DCs  1.96      0.23, 2.7      0.26, 2.58      0.23, 5.4      
0.36, 7.9      0.39, and 8.14      0.5 in naive C57BL/6 and 
B16-, CD1d  hi  -B16  –  , Gal-, B16/Gal-, and CD1d  hi  -B16/Gal  – 
injected mice, respectively, and 1.95      0.73, 2.43      0.31, 
and 2.37      0.21 in naive J    18      /      and B16/Gal- and CD1d  hi  -
B16/Gal  –  injected J    18      /      mice, respectively;   Fig. 6, C  –  E  ). 
These data indicate that DCs begin to mature quickly upon 
injection of tumor/Gal and suggest that DCs must be capturing 
glycolipid for presentation to NKT cells, a known mediator 
of DC maturation (  9, 21  ). 
  To understand how NKT cells might be mobilized to 
mature the splenic DCs, we considered the possibility that 
DCs were cross-presenting glycolipid from phagocytosed 
tumor/Gal. We therefore isolated CD11c     DCs and CD11c        
non-DCs from mice injected with tumor/Gal. The CD11c     
DCs were selectively able to elicit IFN-  	   secretion from liver 
mononuclear cells (MNCs), an enriched source of primary 
NKT cells (  Fig. 6 F  ). In fact, liver MNCs from J    18      /      mice 
that lacked NKT cells did not respond to the DCs (  Fig. 6 F  , 
compare shaded and open bars). To document cross-presen-
tation of     -GalCer from the injected tumor cells, we repeated 
the experiments with CD1d      /      mice in which only the in-
jected tumor cells expressed CD1d. Now the DCs were un-
able to cross-present the glycolipid to NKT cells (  Fig. 6 F  ). 
Collectively, these results indicate that DCs cross-present 
glycolipid after i.v. injection of tumor/Gal in a CD1d-de-
pendent manner. 
  DCs are needed to elicit adaptive immunity to an injection 
of tumor/Gal 
  The data in   Figs. 5 and 6   indicated that DCs were both taking 
up tumor/Gal and undergoing NKT cell  –  dependent matura-
tion in vivo, but to prove that these two events were responsible 
for adaptive T cell immunity, we did two additional experi-
ments. First, we injected CD1d  hi  -B16/Gal tumor cells and 
isolated CD11c     and CD11c    −    cells from the mice 10 h later. 
We then transferred each population to naive mice and looked 
for CD8     T cells specifi  c for melanoma antigens 1 wk later. We 
were able to detect IFN-  	    –  producing CD8     T cells in response 
to trp2 and gp100 peptide in CD11c     cell  –  transferred mice but 
not CD11c        cell  –  transferred mice (  Fig. 7 A  ).   We also injected 
CD1d  hi  -B16/Gal i.v. into CD11c-DTR transgenic mice, 
which allowed for the depletion of the antigen-capturing DCs 
after the injection of DT 1 d later, as previously described (  19  ). 
Treatment with DT totally ablated presentation of trp2 or gp100 
peptides from the injected tumor cells to the T cells (  Fig. 7 B  ). 
These experiments indicate that DCs play a major role in the 
capture and presentation of tumor/Gal to T cells. 
  Figure 5.     Maturing DCs capture tumor/Gal after i.v.   injection.   (A  –  C) 10 million CFSE-labeled CD1d  hi  -EL4 with or without loading with    -GalCer 
were injected into C57BL/6 mice. (A, left) Gated areas indicate subsets of CD11c     DCs,  CD8      DCs, and CD8          DCs. (right) The frequency of uptake of 
CFSE     tumor cells by CD11c     splenic DCs was measured by fl  ow cytometry. (B) CD11c cells were enriched by MACS for analysis by confocal microscopy 
after injection of CFSE-labeled live CD1d  hi  -EL4/Gal cells. (i) Tumor fragments (green), (ii) CD86 to detect mature DCs (red), (iii) DAPI nuclear stain (blue), 
and (iv) a merged image are shown. Bar, 10     m. The data in A and B are representative of three independent experiments (  n    3 per group). (C) The mean 
percentage of DCs taking up CFSE-labeled tumor debris at the indicated time points is shown. (D) As in C, but antigen capture by mature DCs at 10 h was 
quantifi  ed in CD1d  hi -B16      Gal injected with WT C57BL/6 or J   18    /     mice. All data in C and D are means      SEM obtained from three mice per indicated 
time point in two independent experiments per each group.     JEM VOL. 204, October 29, 2007 
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adaptive immunity in vivo. The new approach in this study 
surprisingly begins with several diff  erent mouse tumors as the 
only source of tumor antigen, but the tumor cells are loaded with 
an agonistic glycolipid for NKT cells,     -GalCer (tumor/Gal). 
When relatively low doses of tumor/Gal are injected i.v., we 
    DISCUSSION   
  Tumors are typically poorly immunogenic, in part because 
most tumors fail to express co-stimulatory molecules that are 
needed to induce adaptive T cell immunity. Tumor cells pro-
vide an impetus to identify principles that lead to stronger 
  Figure 6.     In vivo maturation of DCs and cross-presentation of     -GalCer in DCs after administration of tumor/Gal. (A) Spleen cells were ob-
tained at 0, 2, 4, and 6 h after administration of CD1d  hi  -B16/Gal. Low density spleen cells were stained with anti-CD11c  –  PE and CD8    -FITC (to identify 
DCs and their CD8     or  CD8       subsets) and with biotinylated isotype control or CD86 mAb, followed by streptavidin-allophycocyanin. (B) As in A, but DCs 
were tested in three different organs for CD86 expression 6 h after injecting the tumor cells indicated on the left. All data in A, B, and D are representa-
tive of two independent experiments (  n    2 per group). (C) Splenic DCs were analyzed by intracellular cytokine staining for IL-12p40 4 h after immuniza-
tion with tumor/Gal, followed by 4 h of culture in brefeldin A. DCs were identifi  ed with CD11c-allophycocyanin and CD8    -FITC and were subsequently 
fi  xed and stained with PE-conjugated anti  –  IL-12p40 mAb. (D and E) DC maturation studies, as in A and C, were performed in WT and J   18    /     mice  to 
show the NKT cell dependence. Numbers in C and E indicate the percentage of IL-12  –  producing cells in CD8     or  CD8       subsets of CD11c     DCs, and all 
data are representative of three independent experiments (  n    3 per group). (F) To evaluate the cross-presentation of     -GalCer derived from tumor/Gal, 
DCs or non-DCs were isolated by CD11c magnetic beads at 10 h after injecting 5      10 5   CD1d hi  -B16/Gal into WT C57BL/6 or CD1d     /     mice.  10 5   APCs  per 
well were co-cultured with 10  5   liver MNCs per well from C57BL/6 or J   18    /     mice for 48 h. Then, the IFN-  	   from the supernatants was measured by 
ELISA. All data are means      SEM obtained from three independent experiments (  n    5 per group). *, P   
   0.05 for WT versus J   18    /     for liver MNCs; 
**, P   
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to induce DC diff  erentiation or maturation (  9, 21, 22  ), and it 
is more eff  ective in vivo than other stimuli such as Toll-like 
receptor ligands and CD40 ligation (  7  ). 
  This new pathway to enhanced antitumor immunity dif-
fers from immunogenic cell death that takes place with cer-
tain chemotherapies (  6  ). In the latter instance, dying tumor 
cells are recognized by DCs and also provide high mobility 
group box 1 to mature the DCs, whereas in the system de-
scribed in this paper, the tumor cells become immunogenic 
because of cross-presentation of glycolipid to NKT cells, 
which in turn leads to DC maturation. NKT cell  –  based DC 
maturation seems more potent than high mobility group 
box 1  –  based maturation, because higher percentages of ani-
mals resist tumor challenge, the resistance is longer lived, 
and protection can be exerted on highly tumorigenic trans-
plantable tumors. 
  In eff  ect, the injection of glycolipid-loaded tumor cells 
harnesses four of the major components responsible for the 
immunogenicity of antigen-capturing DCs: (a) antigens gain 
access to DCs for antigen processing to take place; (b) the DCs 
mature, including heightened expression of co-stimulatory 
molecules and production of IL-12; (c) the DCs are localized 
in lymphoid tissues in a position to select antigen-reactive 
T cells; and (d) the DEC     CD8     subset of DCs that cross-
presents peptides to CD8     T cells is engaged. We have con-
fi  rmed, using EL4 tumor cells, that the DEC-205     CD8     
subset of DCs cross-presents antigens on MHC class I pro-
ducts (  25, 26  ). 
  Previous observations have shown that innate NK cells 
can amplify MuLV antigen-specifi  c T cell immunity using 
CD70 gene  –  transduced RMA tumor cells (  27  ). It is possible 
that the NK cells were being mobilized by the CD70-trans-
duced tumor cells, leading to the killing, uptake, and matura-
tion of DCs, as shown in this study. 
  We would like to propose that the experiments in this 
paper should be extended into patients with malignancy, 
particularly hematologic malignancies or malignancies with 
fi  nd that it becomes possible to harness many of the diff  erent 
types of lymphocytes that can resist cancer: innate NKT and 
NK cells and adaptive CD4     and CD8     T cells. 
  The use of tumor/Gal (either live or irradiated tumor 
cells) leads to antitumor resistance that seems more eff  ective 
than previous methods (  6, 7, 23  ). First, immunity is induced 
to four diff  erent poorly immunogenic tumors that we have 
tested. Second, we only administer a single low dose of   
  1 
million tumor cells. Third, we measure CD8     T cell immu-
nity to several melanocyte diff  erentiation antigens, again with 
a single dose of B16 tumor. Fourth, the immunity is long 
lived and requires both CD4     and CD8     T cells. 
  A critical feature of tumor cells coated with glycolipid is 
that they are active in stimulating NKT and NK lymphocytes 
if given by the i.v. route (  11  ). As previously noted, NKT cells 
are able to recognize and resist tumor/Gal that are injected 
i.v., even tumors lacking co-stimulatory molecules such as 
CD40, CD80, or CD86. In contrast, these molecules are re-
quired to initiate responses by polyclonal T cells that recognize 
peptides presented on MHC products. After the resistance of 
tumor/Gal by NKT and NK cells, some of the killed tumor 
cells are captured by DCs, and glycolipids also are presented 
on CD1d molecules to additional NKT cells. This leads to 
IL-12 production from DCs, most likely through the expression 
of CD40L that occurs within 4 h of activation of NKT cells 
(  22  ). The IL-12 further mobilizes NK cells in vivo (  24  ). 
Importantly, the maturing DCs are then able to mobilize the 
adaptive T cell limb of immunity, resulting in long-term T cell 
resistance to the tumor. 
  The pivotal step in inducing adaptive immunity to tumor/
Gal is the capture and cross-presentation of glycolipid by 
DCs in vivo. We have observed that DCs from CD1d      /      
mice are unable to present tumor/Gal to NKT cells, indicat-
ing that DCs have to cross-present glycolipid from the tumor 
cells on CD1d, a process that has been reported by Wu et al. 
in tissue culture (  10  ). The ensuing presentation of glycolipid 
by DCs to NKT cells is one of the most potent known means 
  Figure 7.     DCs are required for inducing immunity to tumor/Gal. (A) 10 h after injecting CD1d  hi  -B16/Gal tumor cells, CD11c     and  CD11c  −    cells  were 
isolated, and 3      10 6   CD11c    and 5      10 6   CD11c  −    cells were transferred to naive C57BL/6 mice; spleen cells from uninjected mice served as the negative 
control. 1 wk later, we measured CD8     T cells specifi  c for melanoma antigens (trp2 and gp100) by ELISPOT assay. (B) 1 d after injecting CD1d  hi -B16/Gal  i.v. 
into CD11c-DTR transgenic mice, CD11c     DCs were depleted with DT. 7 d later, we analyzed antigen-specifi  c T cell responses to trp2 or gp100 peptides by 
ELISPOT assays. All data are means obtained from two independent experiments (  n    5 per group). *, P   
   0.05 for CD11c  +   transferred mice versus others 
(left) and DT-treated CD11c-DTR mice versus immunized WT mice (right). SFC, spot-forming cells.     JEM VOL. 204, October 29, 2007 
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were obtained from the American Type Culture Collection, and WEHI-3B 
cells were obtained from the Institute for Fermentation. As previously de-
scribed, for stable introduction of CD1d, pMX-mCD1d-IRES-GFP  –  carry-
ing mCD1d was retrovirally transduced into tumor cells by lipofection, and 
cells were subsequently sorted based on the expression of GFP by FACS-
Vantage (BD Biosciences) (  11  ). 
  Immune assays and in vivo tumor studies.     Mice were immunized i.v. 
with tumor/Gal. In experiments for evaluation of adaptive immunity, im-
munized mice were challenged with parental tumor cells s.c. For immune 
assays, we used 2 mice per group and performed two to four experiments; 
for tumor growth curves, we used 5  –  10 mice per group and performed two 
experiments. Tumor size was measured every 2 d. 
  Assays for priming of antigen-specifi  c T cell immunity.     To identify 
antigen-specifi  c T cells for OVA, spleen cells were isolated 7 d after immu-
nization with OVA carrying tumor cells or OVA peptide  –  pulsed cells and 
challenged in culture for 6 h in the presence or absence of 1     M OVA  257  –  264   
peptide (SIINFEKL, for CD8     T cells) or 10     M OVA  323  –  339   peptide 
(ISQAVHAAHAEINEAGR, for CD4     T cells) with brefeldin A. The cells 
were then stained for cell-surface markers, FITC-conjugated anti-CD4 or 
anti-CD8 mAb, fi  xed with Cytofi  x/Cytoperm Plus permeabilization (BD 
Biosciences), and stained with PE-conjugated anti  –  IFN-  	   mAb. ELISPOT 
assays for melanoma antigen  –  specifi  c IFN-  	    –  secreting cells were performed 
on 96-well fi  ltration plates (Millipore) coated with rat anti  –  mouse IFN-  	   
capture antibody at 10     g/ml (BD Biosciences), as previously described (  17  ). 
CD8     T cells from spleen cells were purifi  ed by positive selection and were 
incubated with Trp2  180  –  188   (SVYDFFVWL; Kb) or gp100  25  –  33   (EGSRN-
QDWL; Db), Tyrp  455  –  463   (TAPDNLGYA; Db), Tyrp  522  –  529   (YAEDYEEL; Kb), 
or Dct  363  –  371  (SQVMNLHNL; Db) peptide-pulsed CD11c     spleen DCs 
for 36 h. Biotinylated anti  –  mouse IFN-  	   detection antibody was added 
at 2     g/ml (BD Biosciences) for 2 h, and spots were developed with an 
avidin  –  peroxidase complex (Vectastain Elite Kit; Vector Laboratories) and 
stable diaminobenzidine substrate (Research Genetics), and were counted 
microscopically. 
  Assays for capture of tumor antigens by DCs in vivo.     DC capture of 
CFSE-labeled tumor cells in vivo was assessed directly by FACS by gating on 
CD11c     spleen cells. We assessed CFSE labeling of CD11c    CD8         and 
CD11c    CD8            DC subsets, as well as reactivity with antibodies to DC 
maturation markers like CD86. Results were verifi  ed by confocal micros-
copy to look for uptake of CFSE-labeled fragments into the DCs. The cyto-
smears were fi  xed for 10 min at room temperature in 4% paraformaldehyde 
in PBS. Cells were stained with anti-biotin  –  CD86 mAb and streptavidin  –
  Alexa Fluor 547 (Invitrogen), and DNA was labeled with DAPI. Cells were 
visualized by confocal microscopy (Leica). 
  Assays for antigen presentation in vivo using OVA as a surrogate 
antigen.     To assess the capacity of tumor/Gal to induce T cell  –  mediated 
immunity, we treated tumor cells with osmotic shock in the presence of 
10 mg/ml OVA protein in hypertonic medium and subsequently treated 
with hypotonic medium; such tumor cells, when injected i.v., are actively 
captured and processed by DCs (  8, 9  ). Using this approach, T cell responses 
were monitored with 2      10  6   CFSE-labeled, CD8     (OT-I), and CD4     
(OT-II) OVA-specifi  c TCR transgenic T cells. The EL4(OVA) tumor cells 
were loaded with     -GalCer for 2 d before osmotic shock with OVA   protein. 
2      10  6   EL4(OVA)/Gal or other controls were given i.v. 1 d after adoptive 
transfer of the OVA-specifi  c TCR transgenic T cells. Spleen cells were 
tested 3 d later to monitor T cell proliferation based on dilution of the CFSE 
signal. OT-I and OT-II T cells were identifi  ed by the expression of CD8 or 
CD4 and V    2 and evaluated for the up-regulation of CD25 or CD44 and 
the down-regulation of CD62L. In some experiments, to assess host DC 
presentation of cell-associated antigens to T cells, CD11c-DTR mice after 
treatment with DT (Sigma-Aldrich) (  19  ) and TAP      /      and CD40      /      mice 
were used as recipients. 
tumor-rich pleural eff  usions and ascites, in which tumor cells 
are readily available for loading with appropriate glycolipids. 
Some human tumor cells express CD1d and are able to pre-
sent endogenous glycolipids as well as     -GalCer to NKT 
cells, eliciting IFN-  	   release and cytolysis (  28, 29  ). The gly-
colipid     -GalCer, although it has not yet been used exten-
sively, has shown safety in humans (  30  –  32  ). Irradiated tumor 
cells, when coated with glycolipid, were active in our exper-
iments, so that a patient  ’  s tumor cells could be subject to ion-
izing irradiation to block tumor growth. A critical unknown 
is the type of tumor cells that should be injected, because 
cancer stem cells or cancer-initiating cells (  33  ) may well rep-
resent the pivotal targets for immune-based resistance to 
malignancy. Research in patients will be required to test 
tumor cells that have been coated with a glycolipid agonist 
for NKT cells as a means to energize several types of tumor-
reactive lymphocytes and several fundamental immunogenic 
features of DCs. 
  MATERIALS AND METHODS 
  Reagents.           −  GalCer was synthesized at the Institute of Physical and Chem-
ical Research.       −  GalCer and vehicle (0.4% DMSO) were diluted in PBS. 
This concentration of DMSO by itself did not elicit innate or adaptive im-
munity to tumors. LPS-free OVA was obtained from Seikagaku Corp. The 
following mAbs were purchased from BD Biosciences: anti  –  mouse CD1d 
(1B1), CD8     (53-6.7), CD11c (HL3), CD19 (1D3), CD25 (PC61), CD44 
(IM7), CD62L (MEL-14), CD40 (3/23), CD70 (FR70), CD80 (16-10A1), 
CD86 (B7-2), CD119 (GR20), CD154 (MR1), NK1.1(PK136), TCR  
   
(H57-597), V    2 TCR (B20.1), H-2K  b   (AF16-88.5), I-A  b  (KH74), IFN-  	   
(XMG1.2), IL-4 (11B11), and IL-12p40/p70 (C15.6) and mouse IgG1 
(A85-1). Biotinylated mAbs were detected with streptavidin-allophycocyanin. 
For fl  ow cytometry of OVA  257  –  264   peptide (SIINFEKL)  –  specifi  c CD8 T cells, 
we used H-2K  b   OVA tetramer  –  SIINFEKL  –  PE (Beckman Coulter). For 
analysis, we used a fl  ow cytometer (FACSCalibur; BD Biosceinces) and 
CELLQuest (BD Biosciences) or FlowJo (Tree Star, Inc.) software. 
  Cell preparation.     DCs were generated from bone marrow progenitors, as 
previously described (  34  ). On day 6, 100 ng/ml     -GalCer was added to 
DCs for 40 h, and 100 ng/ml LPS was added for the last 16 h to mature the 
DCs. Tumor cells were also cultured for 48 h with 500 ng/ml     -GalCer to 
load them with glycolipid. These     -GalCer  –  loaded cells were washed three 
times before injection. To isolate NKT cell  –  enriched MNCs, livers were 
teased into a single suspension, resuspended in a 40/60% Percoll solution 
(GE Healthcare), and centrifuged for 20 min at 900   g   to fl  oat the MNCs. 
To enrich DCs from liver and lung, we digested them with collagenase 
and again fl   oated the DCs on Percoll gradients (  35  ). Before collagenase 
treatement, lungs were perfused with 5 ml of ice-cold PBS and removed. In 
some experiments, splenic DCs were isolated using CD11c magnetic beads 
(Miltenyi Biotec). 
  Mice and cell lines.     Pathogen-free C57BL/6 (B6) and BALB/c female 
mice at 6  –  8 wk old were purchased from CLEA Japan, and B6 CD4      /     , 
CD8      /     , CD40      /     , TAP      /     , and MHC II      /      (B6.129-H2  dlAbl-Ea  ) mice 
were purchased from the Jackson Laboratory. B6 CD1d      /      and J    18      /      
mice have been previously described (  11, 36  ). OT-I and OT-II TCR trans-
genic mice (B6 background) were provided by W. Heath (Walter and Eliza 
Hall Institute of Medical Research, Melbourne, Australia). B6 CD11c-
DTR/GFP transgenic mice were a gift of D. Littman (New York Univer-
sity, New York, NY) and were backcrossed 12 generations to C57BL/6. All 
mice were maintained under specifi  c pathogen-free conditions and studied 
in compliance with institutional guidelines. B16, EL4, and J558 cell lines 2652 ADAPTIVE TUMOR IMMUNITY INDUCED BY GLYCOLIPID-LOADED TUMOR CELLS | Shimizu et al.
        11  .   Shimizu  ,   K.  ,   A.     Goto  ,   M.     Fukui  ,   M.     Taniguchi  , and   S.     Fujii  .   2007  . 
  Tumor cells loaded with     -galactosylceramide induce innate NKT and 
NK cell-dependent resistance to tumor implantation in mice.       J. Immunol.     
  178  :  2853    –    2861  .   
        12  .   Toura  ,   I.  ,   T.     Kawano  ,   Y.     Akutsu  ,   T.     Nakayama  ,   T.     Ochiai  , and   M.   
  Taniguchi  .  1999  .  Inhibition of experimental tumor metastasis by dendritic 
cells pulsed with     -galactosylceramide.       J. Immunol.       163  :  2387    –    2391  .   
        13  .   Fujii  ,   S.  ,   K.     Shimizu  ,   M.     Kronenberg  , and   R.M.     Steinman  .   2002  . 
  Prolonged interferon-  	   producing NKT response induced with     -galac-
tosylceramide-loaded dendritic cells.       Nat. Immunol.       3  :  867    –    874  .   
        14  .   Crowe  ,   N.Y.  ,   J.M.     Coquet  ,   S.P.     Berzins  ,   K.     Kyparissoudis  ,   R.     Keating  , 
  D.G.     Pellicci  ,   Y.     Hayakawa  ,   D.I.     Godfrey  , and   M.J.     Smyth  .   2005  . 
  Diff  erential antitumor immunity mediated by NKT cell subsets in vivo.   
    J. Exp. Med.       202  :  1279    –    1288  .   
        15  .   Denkers  ,   E.Y.  ,   T.     Scharton-Kersten  ,   S.     Barbieri  ,   P.     Caspar  , and   A.   
  Sher  .   1996  .   A role for CD4     NK1.1     T lymphocytes as major histo-
compatibility complex class II  –  independent helper cells in the genera-
tion of CD8     eff  ector function against intracellular infection.       J. Exp. Med.     
  184  :  131    –    139  .   
        16  .   Meyer  ,   E.H.  ,   S.     Goya  ,   O.     Akbari  ,   G.J.     Berry  ,   P.B.     Savage  ,   M.   
  Kronenberg  ,   T.     Nakayama  ,   R.H.     Dekruyff    , and   D.T.     Umetsu  .   2006  . 
  Glycolipid activation of invariant T cell receptor     NK T cells is suf-
fi  cient to induce airway hyperreactivity independent of conventional 
CD4     T cells.       Proc. Natl. Acad. Sci. USA    .   103  :  2782    –    2787  .   
        17  .   Engelhorn  ,   M.E.  ,   J.A.     Guevara-Patino  ,   G.     Noff  z  ,   A.T.     Hooper  ,   O.   
  Lou  ,   J.S.     Gold  ,   B.J.     Kappel  , and   A.N.     Houghton  .   2006  .   Autoimmunity 
and tumor immunity induced by immune responses to mutations in self.   
    Nat. Med.       12  :  198    –    206  .   
        18  .   Guevara-Patino  ,   J.A.  ,   M.E.     Engelhorn  ,   M.J.     Turk  ,   C.     Liu  ,   F.     Duan  , 
  G.     Rizzuto  ,   A.D.     Cohen  ,   T.     Merghoub  ,   J.D.     Wolchok  , and   A.N.   
  Houghton  .   2006  .   Optimization of a self antigen for presentation of mul-
tiple epitopes in cancer immunity.       J. Clin. Invest.       116  :  1382    –    1390  .   
        19  .   Jung  ,   S.  ,   D.     Unutmaz  ,   P.     Wong  ,   G.-I.     Sano  ,   K.     De los Santos  ,   T.   
  Sparwasser  ,   S.     Wu  ,   S.     Vuthoori  ,   K.     Ko  ,   F.     Zavala  ,   et al  .   2002  .   In vivo 
depletion of CD11c     dendritic cells abrogates priming of CD8     T cells 
by exogenous cell-associated antigens.       Immunity    .   17  :  211    –    220  .   
        20  .   Silk  ,   J.D.  ,   I.F.     Hermans  ,   U.     Gileadi  ,   T.W.     Chong  ,   D.     Shepherd  ,   M.   
  Salio  ,   B.     Mathew  ,   R.R.     Schmidt  ,   S.J.     Lunt  ,   K.J.     Williams  ,   et al  .   2004  . 
  Utilizing the adjuvant properties of CD1d-dependent NKT cells in 
T cell-mediated immunotherapy.       J. Clin. Invest.       114  :  1800    –    1811  .   
        21  .   Hermans  ,   I.F.  ,   J.D.     Silk  ,   U.     Gileadi  ,   M.     Salio  ,   B.     Mathew  ,   G.     Ritter  ,   R.   
  Schmidt  ,   A.L.     Harris  ,   L.     Old  , and   V.     Cerundolo  .   2003  .   NKT cells en-
hance CD4     and CD8     T cell responses to soluble antigen in vivo through 
direct interaction with dendritic cells.       J. Immunol.       171  :  5140    –    5147  .   
        22  .   Fujii  ,   S.  ,   K.     Liu  ,   C.     Smith  ,   A.J.     Bonito  , and   R.M.     Steinman  .   2004  . 
  The linkage of innate to adaptive immunity via maturing dendritic cells 
in vivo requires CD40 ligation in addition to antigen presentation and 
CD80/86 costimulation.       J. Exp. Med.       199  :  1607    –    1618  .   
        23  .   Dranoff    ,   G.  ,   E.     Jaff  ee  ,   A.     Lazenby  ,   P.     Golumbek  ,   H.     Levitsky  ,   K.   
  Brose  ,   V.     Jackson  ,   H.     Hamada  ,   D.     Pardoll  , and   R.C.     Mulligan  .   1993  . 
  Vaccination with irradiated tumor cells engineered to secrete murine 
granulocyte-macrophate colony-stimulating factor stimulates potent, spe-
cifi  c, and long-lasting anti-tumor immunity.       Proc. Natl. Acad. Sci. USA    . 
  90  :  3539    –    3543  .   
        24  .   Kitamura  ,   H.  ,   K.     Iwakabe  ,   T.     Yahata  ,   S.     Nishimura  ,   A.     Ohta  ,   Y.     Ohmi  , 
  M.     Sato  ,   K.     Takeda  ,   K.     Okumura  ,   L.     Van Kaer  ,   et al  .   1999  .   The 
natural killer T (NKT) cell ligand     -galactosylceramide demonstrates its 
immunopotentiating eff  ect by inducing interleukin (IL)-12 production 
by dendritic cells and IL-12 receptor expression on NKT cells.       J. Exp. 
Med.       189  :  1121    –    1128  .   
        25  .   Schnorrer  ,   P.  ,   G.M.     Behrens  ,   N.S.     Wilson  ,   J.L.     Pooley  ,   C.M.     Smith  , 
  D.     El-Sukkari  ,   G.     Davey  ,   F.     Kupresanin  ,   M.     Li  ,   E.     Maraskovsky  ,   et al  . 
  2006  .   The dominant role of CD8     dendritic cells in cross-presenta-
tion is not dictated by antigen capture.       Proc. Natl. Acad. Sci. USA    .   103  : 
10729    –    10734  .   
        26  .   Dudziak  ,   D.  ,   A.O.     Kamphorst  ,   G.F.     Heidkamp  ,   V.R.     Buchholz  ,   C.   
  Trumpfheller  ,   S.     Yamazaki  ,   C.     Cheong  ,   K.     Liu  ,   H.W.     Lee  ,   C.G.     Park  , 
  et al  .   2007  .   Diff  erential antigen processing by dendritic cell subsets in 
vivo.       Science    .   315  :  107    –    111  .   
  Statistical analysis.     Diff  erences in survival of treatment groups were ana-
lyzed using the log-rank test. Diff  erences were analyzed using the Mann-
Whitney U test. P   
   0.05 was considered statistically signifi  cant. 
  Online supplemental materials.     Fig. S1 shows CD4     T cells and CD4     
NKT cells in CD4      /      and MHC class II       /      mice by fl  ow cytometry. Fig. 
S2 demonstrates CD4     T and CD8     T cell  –  dependent antitumor resistance 
after vaccination with EL4 thymoma cells loaded with     -GalCer. Fig. S3 
shows the long-term protection against J558 plasmacytoma induced by 
tumor/Gal. Fig. S4 is the induction of T cell response by peptide-pulsed DCs 
via the s.c. route. Fig. S5 shows the uptake of allogeneic spleen cells by the 
CD8     DC subset in the spleen. Fig. S6 shows the maturation of splenic DCs 
in mice given EL4/Gal or CD1d  hi  -EL4/Gal. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20070458/DC1. 
  We thank Ms. Hanae Fujimoto, Akiko Furuno, and Mikiko Fukui for providing 
technical assistance. We also thank Drs. T. Watanabe and T. Kurosaki for critical 
reading of the manuscript. 
  This work is supported by grants from the Ministry of Education, Culture, 
Sports, Science and Technology of Japan (to K. Shimizu and S. Fujii) and grant 
AI13013 from the National Institute of Allergy and Infectious Diseases 
(to R.M. Steinman). 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   5 March 2007 
Accepted:   17 September 2007 
  REFERENCES 
       1  .   Blattman  ,   J.N.  , and   P.D.     Greenberg  .   2004  .   Cancer immunotherapy: 
a treatment for the masses.       Science    .   305  :  200    –    205  .   
       2  .   Yee  ,   C.  ,   J.A.     Thompson  ,   D.     Byrd  ,   S.R.     Riddell  ,   P.     Roche  ,   E.     Celis  , 
and   P.D.     Greenberg  .   2002  .   Adoptive T cell therapy using antigen-spe-
cifi  c CD8     T cell clones for the treatment of patients with metastatic 
melanoma: in vivo persistence, migration, and antitumor eff  ect of trans-
ferred T cells.       Proc. Natl. Acad. Sci. USA    .   99  :  16168    –    16173  .   
       3  .   Dudley  ,   M.E.  ,   J.R.     Wunderlich  ,   P.F.     Robbins  ,   J.C.     Yang  ,   P.     Hwu  , 
  D.J.     Schwartzentruber  ,   S.L.     Topalian  ,   R.     Sherry  ,   N.P.     Restifo  ,   A.M.   
  Hubicki  ,   et al  .   2002  .   Cancer regression and autoimmunity in patients 
after clonal repopulation with antitumor lymphocytes.       Science    .   298  :
  850    –    854  .   
       4  .   Morgan  ,   R.A.  ,   M.E.     Dudley  ,   J.R.     Wunderlich  ,   M.S.     Hughes  ,   J.C.   
  Yang  ,   R.M.     Sherry  ,   R.E.     Royal  ,   S.L.     Topalian  ,   U.S.     Kammula  ,   N.P.   
  Restifo  ,   et al  .   2006  .   Cancer regression in patients after transfer of geneti-
cally engineered lymphocytes.       Science    .   314  :  126    –    129  .   
       5  .   Casares  ,   N.  ,   M.O.     Pequignot  ,   A.     Tesniere  ,   F.     Ghiringhelli  ,   S.     Roux  , 
  N.     Chaput  ,   E.     Schmitt  ,   A.     Hamai  ,   S.     Hervas-Stubbs  ,   M.     Obeid  ,   et al  . 
  2005  .   Caspase-dependent immunogenicity of doxorubicin-induced tumor 
cell death.       J. Exp. Med.       202  :  1691    –    1701  .   
       6  .   Obeid  ,   M.  ,   A.     Tesniere  ,   F.     Ghiringhelli  ,   G.M.     Fimia  ,   L.     Apetoh  ,   J.L.   
  Perfettini  ,   M.     Castedo  ,   G.     Mignot  ,   T.     Panaretakis  ,   N.     Casares  ,   et al  . 
  2007  .   Calreticulin exposure dictates the immunogenicity of cancer cell 
death.       Nat. Med.       13  :  54    –    61  .   
       7  .   Liu  ,   K.  ,   J.     Idoyaga  ,   A.     Charalambous  ,   S.     Fujii  ,   A.     Bonito  ,   J.     Mordoh  , 
  R.     Wainstok  ,   X.F.     Bai  ,   Y.     Liu  , and   R.M.     Steinman  .   2005  .   Innate NKT 
lymphocytes confer superior adaptive immunity via tumor-capturing 
dendritic cells.       J. Exp. Med.       202  :  1507    –    1516  .   
       8  .   Iyoda  ,   T.  ,   S.     Shimoyama  ,   K.     Liu  ,   Y.     Omatsu  ,   Y.     Maeda  ,   K.     Takahara  , 
  Y.     Akiyama  ,   R.M.     Steinman  , and   K.     Inaba  .   2002  .   The CD8     dendritic 
cell subset selectively endocytoses dying cells in culture and in vivo.     
  J. Exp. Med.       195  :  1289    –    1302  .   
       9  .   Fujii  ,   S.  ,   K.     Shimizu  ,   C.     Smith  ,   L.     Bonifaz  , and   R.M.     Steinman  .   2003  . 
  Activation of natural killer T cells by     -galactosylceramide rapidly in-
duces the full maturation of dendritic cells in vivo and thereby acts as an 
adjuvant for combined CD4 and CD8 T cell immunity to a coadminis-
tered protein.       J. Exp. Med.       198  :  267    –    279  .   
        10  .   Wu  ,   D.Y.  ,   N.H.     Segal  ,   S.     Sidobre  ,   M.     Kronenberg  , and   P.B.     Chapman  . 
  2003  .   Cross-presentation of disialoganglioside GD3 to natural killer T cells.   
    J. Exp. Med.       198  :  173    –    181  .   JEM VOL. 204, October 29, 2007 
ARTICLE
2653
        27  .   Kelly  ,   J.M.  ,   P.K.     Darcy  ,   J.L.     Markby  ,   D.I.     Godfrey  ,   K.     Takeda  ,   H.   
  Yagita  , and   M.J.     Smyth  .   2002  .   Induction of tumor-specifi  c T cell mem-
ory by NK cell-mediated tumor rejection.       Nat. Immunol.       3  :  83    –    90  .   
        28  .   Dhodapkar  ,   M.V.  ,   M.D.     Geller  ,   D.H.     Chang  ,   K.     Shimizu  ,   S.     Fujii  , 
  K.M.     Dhodapkar  , and   J.     Krasovsky  .   2003  .   A reversible defect in natural 
killer T cell function characterizes the progression of premalignant to 
malignant multiple myeloma.       J. Exp. Med.       197  :  1667    –    1676  .   
        29  .   Dhodapkar  ,   K.M.  ,   B.     Cirignano  ,   F.     Chamian  ,   D.     Zagzag  ,   D.C.     Miller  , 
  J.L.     Finlay  , and   R.M.     Steinman  .   2004  .   Invariant natural killer T cells are 
preserved in patients with glioma and exhibit antitumor lytic activity fol-
lowing dendritic cell-mediated expansion.       Int. J. Cancer    .   109  :  893    –    899  .   
        30  .   Giaccone  ,   G.  ,   C.J.     Punt  ,   Y.     Ando  ,   R.     Ruijter  ,   N.     Nishi  ,   M.     Peters  , 
  B.M.     von Blomberg  ,   R.J.     Scheper  ,   H.J.     van der Vliet  ,   A.J.     van den 
Eertwegh  ,   et al  .   2002  .   A phase I study of the natural killer T-cell ligand 
    -galactosylceramide (KRN7000) in patients with solid tumors.       Clin. 
Cancer Res.       8  :  3702    –    3709  .   
        31  .   Chang  ,   D.H.  ,   K.     Osman  ,   J.     Connolly  ,   A.     Kukreja  ,   J.     Krasovsky  ,   M.   
  Pack  ,   A.     Hutchinson  ,   M.     Geller  ,   N.     Liu  ,   R.     Annable  ,   et al  .   2005  . 
  Sustained expansion of NKT cells and antigen-specifi  c T cells after in-
jection of     -galactosyl-ceramide  –  loaded mature dendritic cells in cancer 
patients.       J. Exp. Med.       201  :  1503    –    1517  .   
        32  .   Ishikawa  ,   A.  ,   S.     Motohashi  ,   E.     Ishikawa  ,   H.     Fuchida  ,   K.     Higashino  ,   M.   
  Otsuji  ,   T.     Iizasa  ,   T.     Nakayama  ,   M.     Taniguchi  , and   T.     Fujisawa  .   2005  . 
  A phase I study of     -galactosylceramide (KRN7000)-pulsed dendritic 
cells in patients with advanced and recurrent non-small cell lung cancer.   
    Clin. Cancer Res.       11  :  1910    –    1917  .   
        33  .   Polyak  ,   K.  , and   W.C.     Hahn  .   2006  .   Roots and stems: stem cells in can-
cer.       Nat. Med.       12  :  296    –    300  .   
        34  .   Inaba  ,   K.  ,   M.     Inaba  ,   N.     Romani  ,   H.     Aya  ,   M.     Deguchi  ,   S.     Ikehara  , 
  S.     Muramatsu  , and   R.M.     Steinman  .   1992  .   Generation of large num-
bers of dendritic cells from mouse bone marrow cultures supplemented 
with granulocyte/macrophage colony-stimulating factor.       J. Exp. Med.     
  176  :  1693    –    1702  .   
        35  .   Inaba  ,   K.  ,   N.     Romani  ,   G.     Schuler  ,   A.     Mirza  , and   R.M.     Steinman  . 
  1997  . Generation of dendritic cells from proliferating mouse bone mar-
row progenitors.   In   Current Protocols in Immunology. J.E. Coligan, 
A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, edi-
tors. Greene Publishing Associates and Wiley-Interscience, New York. 
3.7.7  –  3.7.15.   
        36  .   Mendiratta  ,   S.K.  ,   W.D.     Martin  ,   S.     Hong  ,   A.     Boesteanu  ,   S.     Joyce  , and 
  L.     Van Kaer  .   1997  .   CD1d1 mutant mice are defi  cient in natural T cells 
that promptly produce IL-4.       Immunity    .   6  :  469    –    477  .                     